Headquarters
China
Every company in the roster headquartered in China.
Research
Compare company financial metrics
Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.
Views
105 of 105 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Jiangsu Hengrui Pharmaceuticals600276 · SSE | 56 assets: 27 Ph 3, 16 Ph 2, 13 Ph 1 | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Oct 2026HRS-6209 · Phase 1/2 |
 Qilu PharmaceuticalPrivate | 18 assets: 10 Ph 3, 6 Ph 2, 2 Ph 1 | QLM3003Phase 3 · Atopic DermatitisPartial signal | 31 Oct 2026QL1706 · Phase 2 |
 Hansoh Pharmaceutical Group3692 · HKEX | 15 assets: 8 Ph 3, 4 Ph 2, 3 Ph 1 | HS-20094Phase 3 · ObesityReliable signal | 30 Oct 2026HS-20118 · Phase 1 |
 Innovent Biologics1801 · HKEX | 13 assets: 9 Ph 3, 2 Ph 2, 2 Ph 1 | IBI305Phase 3 · Non-Small Cell Lung CancerReliable signal | 31 Oct 2026IBI3003 · Phase 1/2 |
 Sino Biopharmaceutical1177 · HKEX | 13 assets: 1 approved, 6 Ph 3, 3 Ph 2, 3 Ph 1 | CulmerciclibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Dec 2026Culmerciclib · Phase 3 |
 CSPC Pharmaceutical Group1093 · HKEX | 11 assets: 8 Ph 3, 2 Ph 2, 1 other | DBPR108Phase 3 · Type 2 DiabetesReliable signal | 10 Oct 2026Ammoxetine · Phase 1 |
 Haisco Pharmaceutical Group002653 · SZSE | 9 assets: 5 Ph 3, 1 Ph 2, 2 Ph 1, 1 other | Anrikefon (HSK21542)Phase 3 · Chronic Kidney DiseaseReliable signal | 31 Oct 2026HSK44459 · Phase 2 |
 Luye Pharma Group2186 · HKEX | 9 assets: 2 approved, 3 Ph 3, 1 Ph 2, 3 Ph 1 | Ansofaxine hydrochloridePhase 3 · Major Depressive DisorderReliable signal | 28 Feb 2027Ansofaxine hydrochloride · Approved |
 Shenzhen Salubris Pharmaceuticals002294 · SZSE | 7 assets: 3 Ph 3, 4 Ph 2 | EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal | 31 Oct 2026JK07 · Phase 2 |
 Sunshine Lake PharmaPrivate | 7 assets: 2 Ph 3, 1 Ph 2, 4 Ph 1 | Clifutinib BesylatePhase 3 · Acute Myeloid Leukemia | 30 Dec 2026HEC169096 · Phase 1/2 |
 Keymed Biosciences2162 · HKEX | 6 assets: 3 Ph 3, 2 Ph 2, 1 Ph 1 | stapokibartPhase 3 · Atopic DermatitisReliable signal | 2 Nov 2026CM512 · Phase 2 |
 Hangzhou Zhongmei Huadong Pharmaceutical000963 · SZSE | 5 assets: 3 Ph 3, 1 Ph 1, 1 other | HDG1901Phase 3 · Type 2 DiabetesPartial signal | 10 Oct 2026HDM1002 · Phase 3 |
 Ascletis Pharma1672 · HKEX | 4 assets: 3 Ph 3, 1 Ph 1 | DenifanstatPhase 3 · MASH / NASHReliable signal | Jul 2028ASC30 · Phase 3 |
 BeBetter Med688759 · SSE STAR Market | 4 assets: 2 Ph 3, 2 Ph 2 | BEBT-908Phase 3 · Multiple MyelomaWeak signal | Jun 2027BEBT-109 · Phase 2 |
 Beijing QL BiopharmaceuticalPrivate | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | ZT002Phase 3 · ObesityReliable signal | 3 Dec 2026zovaglutide · Phase 1 |
| 4 assets: 4 Ph 3 | stapokibartPhase 3 · Atopic DermatitisReliable signal | 11 Oct 2026HB1801 · Phase 2 | |
 Chipscreen Biosciences688321 · SSE | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | ChiglitazarPhase 3 · Type 2 DiabetesReliable signal | 26 Oct 2026Chiglitazar · Phase 1 |
 Gan & Lee Pharmaceuticals603087 · SSE | 4 assets: 2 Ph 3, 2 Ph 2 | GZR18Phase 3 · ObesityPartial signal | 11 Dec 2026GZR18 · Phase 3 |
 Tasly Pharmaceutical Group600535 · SSE | 4 assets: 4 Ph 2 | QiShenYiQiPhase 2 · Heart FailurePartial signal | 31 Dec 2026Jia Shen Tablet · Phase 2 |
 Huahui HealthPrivate | 3 assets: 1 Ph 2, 2 Ph 1 | HH-003 (Libevitug)Phase 2 · Chronic Hepatitis B | Aug 2027HH160 · Phase 1 |
 Newsoara BiopharmaPrivate | 3 assets: 2 Ph 3, 1 Ph 1 | HPP737Phase 3 · PsoriasisPartial signal | 1 Dec 2026HY1272 · Phase 1 |
 PegBioPrivate | 3 assets: 2 Ph 3, 1 Ph 2 | PB-119Phase 3 · Type 2 DiabetesReliable signal | None on record |
 Regend TherapeuticsPrivate | 3 assets: 1 Ph 3, 2 Ph 1 | REGEND001Phase 3 · Chronic Obstructive Pulmonary DiseasePartial signal | 15 Oct 2026REGEND007 · Phase 1 |
 Sciwind BiosciencesPrivate | 3 assets: 2 Ph 3, 1 Ph 1 | ecnoglutidePhase 3 · ObesityReliable signal | 5 Jan 2027ecnoglutide · Phase 1/2 |
| 2 assets: 1 Ph 3, 1 Ph 2 | AZD3759Phase 2/3 · Non-Small Cell Lung CancerPartial signal | 23 Apr 2028Zorifertinib · Phase 1 | |
| 2 assets: 2 Ph 1 | NK520Phase 1 · Acute Myeloid LeukemiaWeak signal | Jun 2027NK510 · Phase 1 | |
 BrightGene Bio-Medical Technology688166 · SSE | 2 assets: 1 Ph 3, 1 Ph 1 | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 |
| 2 assets: 1 Ph 3, 1 Ph 2 | Purinostat MesylatePhase 3 · Multiple Myeloma | 30 Dec 2026Purinostat Mesylate · Phase 2 | |
 Hebei Senlang BiotechnologyPrivate | 2 assets: 2 Ph 2 | SENL103Phase 1/2 · Multiple MyelomaWeak signal | 1 Feb 2028SENL103 · Phase 1/2 |
 Hua Medicine2552 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | DorzagliatinPhase 3 · Type 2 DiabetesPartial signal | None on record |
 ImmuneOnco Biopharmaceuticals1541 · HKEX | 2 assets: 2 Ph 2 | IMM2510Phase 2 · Non-Small Cell Lung Cancer | 20 May 2027ImmuneOnco anti-PAH candidate (IMC-003) · Phase 1 |
| 2 assets: 1 Ph 3, 1 Ph 1 | VCT220Phase 3 · ObesityReliable signal | 30 Oct 2026VCT220 · Phase 2 | |
 Jiangsu Nhwa Pharmaceutical Co., Ltd.002262 · SZSE | 2 assets: 1 Ph 2, 1 Ph 1 | NH102Phase 2 · Major Depressive DisorderPartial signal | None on record |
 Laekna Limited2105 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | AfuresertibPhase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Oct 2026Afuresertib · Phase 3 |
| 2 assets: 1 Ph 2, 1 Ph 1 | LT-002-158Phase 1/2 · Atopic Dermatitis | 17 Feb 2028LT-002-158 · Phase 1/2 | |
| 2 assets: 2 Ph 3 | YL201Phase 3 · Non-Small Cell Lung Cancer | Nov 2026YL202 · Phase 2 | |
| 2 assets: 1 Ph 3, 1 Ph 2 | JS105Phase 3 · HR+/HER2- Metastatic Breast Cancer | 26 Feb 2027JS105 · Phase 1/2 | |
Shanghai Pharmaceuticals Holding2607 · SSE | 2 assets: 2 Ph 3 | sitokirenPhase 3 · HypertensionPartial signal | 1 Dec 2026SPH4336 · Phase 2/3 |
| 2 assets: 2 Ph 3 | SupaglutidePhase 2/3 · Type 2 DiabetesReliable signal | 30 Apr 2027efsubaglutide alfa · Phase 1 | |
| 2 assets: 2 Ph 2 | INV-6452Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 4 Feb 2028INV-6452 · Phase 1/2 | |
 Suzhou AlphamabPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | EnvafolimabPhase 3 · Non-Small Cell Lung CancerWeak signal | 30 Dec 2026KN060 · Phase 1 |
| 2 assets: 1 Ph 3, 1 Ph 2 | YK-209APhase 3 · Non-Small Cell Lung Cancer | None on record | |
 Suzhou Siran BiotechnologyPrivate | 2 assets: 2 Ph 1 | SA030Phase 1 · Obesity | 30 Mar 2027SA1211 injection · Phase 1 |
 Suzhou Yabao PharmaceuticalPrivate | 2 assets: 2 Ph 2 | SY-004Phase 2 · Type 2 DiabetesPartial signal | None on record |
 Tianjin Hemay PharmaceuticalPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | Hemay005Phase 3 · Ulcerative ColitisPartial signal | None on record |
Tonghua Dongbao Pharmaceutical600867 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record |
| 2 assets: 1 Ph 3, 1 Ph 1 | UBT251Phase 3 · Obesity | 25 Oct 2026UBT38006 · Phase 1 | |
| 1 asset: 1 Ph 2 | AC-101Phase 2 · Ulcerative Colitis | None on record | |
| 1 asset: 1 Ph 1 | Anhui HygeianCells EE001Phase 1 · Heart FailureWeak signal | None on record | |
 Asieris Pharmaceuticals688176 · SSE STAR Market | 1 asset: 1 Ph 1 | APL-1401Phase 1 · Ulcerative ColitisPartial signal | None on record |
| 1 asset: 1 Ph 2 | BioTTT001Phase 1/2 · Non-Small Cell Lung Cancer | 31 Jul 2027BioTTT001 · Phase 1/2 | |
Beijing Dongfang BiotechPrivate | 1 asset: 1 Ph 3 | exendin-4 Fc fusion (JY09)Phase 3 · Type 2 DiabetesWeak signal | None on record |
 Beijing Joekai BiotechnologyPrivate | 1 asset: 1 Ph 2 | 50561Phase 2 · Alzheimer's DiseasePartial signal | None on record |
| 1 asset: 1 Ph 1 | mulberry twig alkaloidsPhase 1 · ObesityWeak signal | None on record | |
 Benethera BiotechnologyPrivate | 1 asset: 1 Ph 1 | BDHK-2009Phase 1 · Ulcerative Colitis | None on record |
 Biotroy TherapeuticsPrivate | 1 asset: 1 Ph 2 | BT02Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2027BT02 · Phase 1 |
| 1 asset: 1 Ph 3 | DA-302168SPhase 3 · ObesityPartial signal | 9 Jul 2027DA-302168S · Phase 3 | |
| 1 asset: 1 Ph 3 | YogliptinPhase 3 · Type 2 DiabetesPartial signal | None on record | |
 China Resources Sanjiu Medical & Pharmaceutical000999 · SZSE | 1 asset: 1 Ph 3 | Shenfu injectionPhase 2/3 · Heart Failure | None on record |
| 1 asset: 1 Ph 1 | KRAS-specific Autologous TCR-T cellPhase 1 · Non-Small Cell Lung Cancer | 30 Nov 2028KRAS-specific Autologous TCR-T cell · Phase 1 | |
| 1 asset: 1 Ph 2 | CTS2190Phase 1/2 · Non-Small Cell Lung Cancer | None on record | |
| 1 asset: 1 Ph 2 | HEC88473Phase 2 · ObesityPartial signal | None on record | |
| 1 asset: 1 Ph 2 | ES102Phase 2 · Non-Small Cell Lung Cancer | 28 Feb 2027ES102 · Phase 2 | |
 Evopoint Biosciences Inc.Private | 1 asset: 1 Ph 2 | ASP546CPhase 1/2 · Non-Small Cell Lung Cancer | None on record |
| 1 asset: 1 Ph 1 | INN805Phase 1 · Non-Small Cell Lung Cancer | Dec 2026INN805 · Phase 1 | |
 Grit BiotechnologyPrivate | 1 asset: 1 Ph 1 | GT737Phase 1 · Acute Myeloid Leukemia | Jun 2030GT737 · Phase 1 |
 Guangdong Raynovent BiotechPrivate | 1 asset: 1 Ph 3 | RAY1225Phase 3 · Obesity | 14 Oct 2026RAY1225 · Phase 1 |
| 1 asset: 1 Ph 1 | MN-08Phase 1 | 30 Mar 2028MN-08 · Phase 1 | |
 HELP TherapeuticsPrivate | 1 asset: 1 Ph 3 | HiCM-188 (allogeneic iPSC-cardiomyocytes)Phase 3 · Heart FailurePartial signal | 10 Nov 2026HiCM-188 (allogeneic iPSC-cardiomyocytes) · Phase 1/2 |
| 1 asset: 1 Ph 1 | HPB-092Phase 1 · Acute Myeloid Leukemia | Jun 2027HPB-092 · Phase 1 | |
| 1 asset: 1 Ph 1 | WBC100Phase 1 · Acute Myeloid Leukemia | None on record | |
| 1 asset: 1 Ph 1 | TGI-5Phase 1 · Non-Small Cell Lung Cancer | 31 Oct 2027TGI-5 · Phase 1 | |
 HighTide BiopharmaPrivate | 1 asset: 1 Ph 3 | HTD1801Phase 3 · Type 2 DiabetesReliable signal | None on record |
| 1 asset: 1 Ph 1 | IBR733Phase 1 · Acute Myeloid Leukemia | 1 Jul 2027IBR733 · Phase 1 | |
 InventisBio688382 · SSE STAR Market | 1 asset: 1 Ph 3 | D-2570Phase 3 · Ulcerative ColitisPartial signal | 31 Oct 2026D-2570 · Phase 1 |
| 1 asset: 1 Ph 3 | FHND9041Phase 3 · Non-Small Cell Lung Cancer | None on record | |
| 1 asset: 1 Ph 3 | TH-SC01Phase 3 · Crohn's DiseaseWeak signal | 28 Dec 2026TH-SC01 · Phase 3 | |
 LyncBio TherapeuticsPrivate | 1 asset: 1 Ph 1 | LYNC-101Phase 1 · Ulcerative Colitis | 19 Mar 2027LYNC-101 · Phase 1 |
 MindRank AIPrivate | 1 asset: 1 Ph 3 | MDR-001Phase 3 · Obesity | Jun 2027MDR-001 · Phase 3 |
 Nanjing Immunophage BiotechPrivate | 1 asset: 1 Ph 2 | IPG11406Phase 2 · Ulcerative ColitisPartial signal | 1 Dec 2028IPG11406 · Phase 2 |
 Nanjing RegeneCore BiotechPrivate | 1 asset: 1 Ph 2 | RC1416Phase 2 · Chronic Obstructive Pulmonary Disease | 25 Oct 2027RC1416 · Phase 2 |
| 1 asset: 1 Ph 2 | atamparibPhase 1/2 · Non-Small Cell Lung Cancer | 31 Jul 2028atamparib · Phase 1/2 | |
 Phrontline BiopharmaPrivate | 1 asset: 1 Ph 3 | TJ101Phase 3 · Non-Small Cell Lung Cancer | 30 Dec 2026TJ101 · Phase 1 |
| 1 asset: 1 Ph 1 | PLB-002Phase 1 · Non-Small Cell Lung Cancer | 30 Jun 2027PLB-002 · Phase 1 | |
| 1 asset: 1 Ph 2 | HS-IT101Phase 2 · Non-Small Cell Lung Cancer | 31 Dec 2027HS-IT101 · Phase 2 | |
S-Evans BiosciencesPrivate | 1 asset: 1 Ph 2 | Menstrual blood-derived mesenchymal stem cells (MenSCs)Phase 1/2 | None on record |
| 1 asset: 1 Ph 2 | ALK202Phase 2 · Non-Small Cell Lung Cancer | Dec 2027ALK202 · Phase 1 | |
| 1 asset: 1 Ph 3 | TTYP01Phase 3 · Alzheimer's Disease | 23 Oct 2028TTYP01 · Phase 2 | |
| 1 asset: 1 Ph 3 | Sodium oligomannatePhase 3 · Alzheimer's DiseaseReliable signal | None on record | |
 Shanghai HEP PharmaceuticalPrivate | 1 asset: 1 Ph 3 | hepalatidePhase 3 · Type 2 Diabetes | Jun 2027hepalatide · Phase 3 |
| 1 asset: 1 Ph 2 | U32 CAR-TPhase 1/2 · Acute Myeloid Leukemia | 31 Dec 2027U32 CAR-T · Phase 1/2 | |
| 1 asset: 1 Ph 1 | MS-553Phase 1 · Type 2 Diabetes | 30 Oct 2026MS-553 · Phase 1 | |
 Sihuan Pharmaceutical Holdings0460 · HKEX | 1 asset: 1 Ph 3 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | None on record |
 Sinotau Pharmaceutical GroupPrivate | 1 asset: 1 Ph 2 | XTR003Phase 2 · Heart Failure | None on record |
| 1 asset: 1 Ph 2 | LM103Phase 2 · Non-Small Cell Lung Cancer | 31 Dec 2027LM103 · Phase 2 | |
| 1 asset: 1 Ph 2 | T101Phase 2 · Chronic Hepatitis B | None on record | |
 TrueLab BiopharmaceuticalPrivate | 1 asset: 1 Ph 1 | TL-003Phase 1 · Ulcerative Colitis | Apr 2027TL-003 · Phase 1 |
| 1 asset: 1 Ph 2 | TSN1611Phase 1/2 · Non-Small Cell Lung Cancer | 30 Oct 2026TSN1611 · Phase 1/2 | |
 Vincentage PharmaPrivate | 1 asset: 1 Ph 3 | VCT220Phase 3 · ObesityReliable signal | 30 Oct 2026VCT220 · Phase 2 |
| 1 asset: 1 Ph 3 | QR12000Phase 3 · HypertensionPartial signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).